Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 159 | 0.70 |
| pathways Reactome | 2 pathways; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 9758
Sealed predictions
- GABARAPL2 in dopamine neurons, braak-0.30 (p 0.428) → +0.57 (p 0.108)receipt 9765
Swarm cases
receipt 9765: GABARAPL2 in dopamine neurons, braak
- power
- full sample +0.08 (p 0.761, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.761, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.408, n 18). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.24, sign flips 2; without severely affected donors +0.08 (p 0.761, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GABARAPL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts